91黑料 experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Shelley McLendon discusses the importance of disease surveillance, developments in early outbreak detection, and the role of smart data reporting and adaptive trial designs.
-
This news article, first published on , outlines how 91黑料 has been selected by
-
Considerations for vaccine efficacy trials targeting emerging infectious diseases
Following the COVID-19 pandemic, Shelley McLendon outlines what lessons must be learned to prevent future other emerging infectious diseases developing on a similar scale.
This article is taken from European Biopharmaceutical Review October 2022, pages 16-18. Samedan Ltd
-
How this top CEO helped Pfizer turbocharge the covid-19 vaccine
Steve Cutler discusses 91黑料's covid-19 efforts, the importance of building a good team, and more in this interview with Investor's Business Daily.
-
Shelley Mclendon, Vice President, Vaccine and Infectious Disease, offers her insights on .
This article is taken from European Biopharmaceutical Review April 2022, pages 8-10. Samedan Ltd.
-
Shelley McLendon, Vice President, Vaccines and Infectious Disease, discusses .
-
how glycomics is joining genomics and proteomics in the study of disease mechanisms and the development of novel therapeutics.
-
Dr. Johan Du Toit, Executive Director, Internal Medicine, considers strategies from COVID era clinical trials for .
-
In this report, Dr Steve Cutler describes 91黑料’s efforts to combat the COVID-19 pandemic and how the crisis has pushed new digital technologies forward
-
Shelley McLendon considers the knock-on effect of COVID-19 for other infectious diseases, and what we can do to speed up development future vaccines
